Unicycive Q1 net loss $14.6M ($0.97/sh) vs $3.5M loss YoY; cash $24.3M from $30M upfront financing

Unicycive Therapeutics, Inc.

2023-Q1 EPS reported -$0.97 revenue$675,000

Net loss of $14.6M ($0.97/sh) compared to $3.5M ($0.24/sh) in Q1 2022; includes $10.4M change in warrant liability.
Licensing revenue $0.7M from Lotus Pharma agreement for Renazorb in South Korea signed February 2023.
Cash and cash equivalents $24.3M (Dec 2022: $0.5M) after $30M upfront from up to $130M private placement.
Plans to file NDA for Renazorb by Q3 2023 with potential approval and launch in 2024.
UNI-494 Phase 1 first cohort enrolled; plans to file IND in 2024 for Phase 2 trial in AKI.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Unicycive Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $0.7 million, net income $14.6 million, EPS $0.97 per share of common stock.

Period: the first quarter ended March 31, 2023
Revenue: $0.7 million
Net income: $14.6 million
EPS: $0.97 per share of common stock
Result: reported results

Exact text from the filing

Renal Association Congress (ERA 2023) taking place in Milan, Italy from June 15-18, 2023. Financial Results for the First Quarter Ended March 31, 2023 Licensing revenues were $0.7 million for the quarter ended March 31, 2023 due to a licensing agreement executed in February 2023. Research and development expenses for the quarter ended March 31, 2023 were $3.0

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-040217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.